Antithrombin Deficiency

Because antithrombin thrombin, factor Xa, factor IXa and factor XIa inhibits an antithrombin deficiency predisposes those affected for venous thrombosis.

Because antithrombin thrombin, factor Xa, factor IXa and factor XIa inhibits an antithrombin deficiency predisposes those affected for venous thrombosis.

(See also Thrombotic diseases at a glance.) Because antithrombin thrombin, factor Xa, factor IXa and factor XIa inhibits an antithrombin deficiency predisposes those affected for venous thrombosis. Antithrombin inhibits a protein thrombin and factors Xa, IXa and XIa, which in turn thrombosis is inhibited. When the prevalence of heterozygous deficiency of antithrombin is about 0.2-0.4%. About half of those affected developed venous thrombosis. The homozygous deficiency is usually already deadly during Fetalstadiums. An acquired deficiency occurs in patients with disseminated intravascular coagulation, liver disease, or nephrotic syndrome during therapy with heparin. Heparin exerts its anticoagulant effects by activating antithrombin. The laboratory examination is performed in patients with unexplained blood clotting and comprises determining the degree of KAaazität the plasma of the patients, to inhibit thrombin in the presence of heparin. Warfarin therapy to prevent venous thromboembolism as prophylaxis against venous thrombosis is the therapy used with warfarin. It is not yet known if the newer oral anticoagulants, either thrombin (dabigatran) or factor Xa (z. B. rivaroxaban, apixaban) inhibit can be used for this disorder instead of warfarin.

Health Life Media Team

Leave a Reply